Enterprise Value

64.4M

Cash

16.21M

Avg Qtr Burn

-24.85M

Short % of Float

16.95%

Insider Ownership

22.98%

Institutional Own.

36.09%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ENTADFI™ (tadalafil and finasteride) Details
Benign prostatic hyperplasia (BPH)

Approved

Update

Enobosarm +/- abemaciclib Details
HER2-expressing cancers, ER+/HER2- breast cancer

Phase 3

Data readout

Phase 3

Initiation

Sabizabulin (VERU-111) + Enobosarm Details
Triple-negative breast cancer , Cancer

Failed

Discontinued

VERU-100 Details
Prostate cancer, Cancer

Failed

Discontinued

Failed

Discontinued

Sabizabulin (VERU-111) Details
Castration-resistant prostate cancer

Failed

Discontinued